Soligenix (SNGX) Amortization of Deferred Charges (2015 - 2026)
Soligenix's (SNGX) quarterly Amortization of Deferred Charges came in at $28025.0 in Q1 2026, down 12.06% YoY from $31867.0 in Q1 2025, and up 2.09% on a QoQ basis from $27450.0 in Q4 2025.
Soligenix (SNGX) Amortization of Deferred Charges (2015 - 2026) Analysis & Trends
Soligenix (SNGX) has 8 years of Amortization of Deferred Charges data on file, last reported at $28025.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges fell 12.06% year-over-year to $28025.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110760.0 (down 10.3% YoY) and the FY2025 annual result came in at $114602.0, down 5.19% from the prior year.
- Amortization of Deferred Charges advanced to $28025.0 in Q1 2026, from $27450.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $98635.0 in Q4 2023 to a low of -$44788.0 in Q4 2022.
- A 5-year average of $24481.7 and a median of $28025.0 in 2026 frame the typical range for Amortization of Deferred Charges.
- The widest YoY moves for Amortization of Deferred Charges: up 320.23% in 2023, down 262.14% in 2023.
- Tracing SNGX's Amortization of Deferred Charges over 5 years: stood at -$44788.0 in 2022, then surged by 320.23% to $98635.0 in 2023, then sank by 68.38% to $31185.0 in 2024, then dropped by 11.98% to $27450.0 in 2025, then climbed by 2.09% to $28025.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $28025.0 (Q1 2026), $27450.0 (Q4 2025), and $26889.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28,610.00 |
| Jun 30, 2026 | 28,610.00 |
| Mar 31, 2026 | 28,025.00 |
| Mar 31, 2026 | 28,025.00 |
| Dec 31, 2025 | 27,450.00 |
| Dec 31, 2025 | 27,450.00 |
| Sep 30, 2025 | 26,889.00 |
| Sep 30, 2025 | 26,889.00 |
| Jun 30, 2025 | 28,396.00 |
| Jun 30, 2025 | 28,396.00 |
| Mar 31, 2025 | 31,867.00 |
| Mar 31, 2025 | 31,867.00 |
| Dec 31, 2024 | 31,185.00 |
| Dec 31, 2024 | 31,185.00 |
| Sep 30, 2024 | 30,531.00 |
| Sep 30, 2024 | 30,531.00 |
| Jun 30, 2024 | 29,890.00 |
| Jun 30, 2024 | 29,890.00 |
| Mar 31, 2024 | 29,265.00 |
| Mar 31, 2024 | 29,265.00 |